ATM and B-cell chronic lymphocytic leukemia: Since ibrutinib has been proven to be one of the most optimal therapeutic strategies for fludarabine-relapsed/refractory CLL patients [54], and olaparib is highly effective in del(11q)/ATM-mutated CLL cells, the combination of both drugs could be effective for del(11q)-relapsed/refractory CLL patients.